Noble Life Sciences (Gaithersburg, MD), in collaboration with ImQuest BioSciences (Frederick, MD), has successfully developed a neutropenic mouse thigh model of infection and demonstrated its use in a study evaluating vancomycin for the treatment of Staphylococcus aureus infection. The model will serve as a new Noble service for the evaluation of the efficacy of novel anti-microbial compounds in the treatment of microbial infections.
Complicated skin and soft tissue infections are frequently encountered in clinical practice and are a significant cause of morbidity and mortality in hospitalized patients. The neutropenic mouse thigh model of infection has been used extensively to test and benchmark antimicrobial drugs leading to a significant impact on our current knowledge of antimicrobial pharmacology. This model allows the quantitative comparison of different agents and different dosing regimes and the determination of the time-course of antimicrobial activity under conditions optimal for efficacy, i.e., neutropenia.